Haemonetics Corporation Share Price & Technical Analysis

HAE · $65.49 (+5.73%)

Healthcare / Medical Devices

AI Score 67 · Neutral

$65.49

+5.73%

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information techn

Price chart

Seasonality

May has 4 positive and 1 negative years (last 5 years shown)

9% return in May, 0% avg return in past 3 year May month.

-17% return in 2026, 11% avg return in past 3 years.

Swipe sideways to see all months →

JanFebMarAprMayJunJulAugSepOctNovDecYr
26-17%-5%-11%7%9%-17%
25-12%-4%-3%-1%7%11%0%-26%-11%3%63%-1%26%
24-10%-5%17%7%-9%-2%9%-16%7%-11%22%-11%-1%
236%-9%7%2%1%0%9%-3%-1%-5%-5%6%8%
22-9%18%9%-20%25%3%6%9%-1%13%0%-8%44%

Monthly return % by calendar month · historical pattern, not a forecast

AI snapshotScore 67/100

Neutral · Emerging · Strong

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$2.50B

P/E ratio

14.82

52W high

$87.32

52W low

$47.32

Volume

10,36,865

Beta

0.53

Related stocks in Healthcare

Frequently asked questions

What is Haemonetics Corporation share price today?
Haemonetics Corporation (HAE) last traded around $65.49 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does HAE have?
StockPro currently tracks 1 active signal(s) for HAE, including breakouts, momentum, and volume patterns. See the signals panel on this page.
How can I analyze Haemonetics Corporation stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro